SCHEMBL5923085

SCHEMBL5923085

Cc1cc(C)nc(NC(=N)Nc2ccc(Oc3ccc(Cl)cc3)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CHRNB2 P17787 1/20 0.44
▸ CHRNB4 P30926 1/20 0.44
▸ CHRNA3 P32297 1/20 0.44
▸ CHRNA4 P43681 1/20 0.44
▸ PHGDH O43175 2/20 0.43
▸ ALDH1A1 P00352 5/20 0.42
▸ NPSR1 Q6W5P4 5/20 0.42
▸ RAB9A P51151 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP8 Q96LD8 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5923207 0.89 SMN1; SMN2 (0.52) CYP1A2CYP3A4CHRNB2CHRNB4CHRNA3
SCHEMBL5923379 0.84 GBA1 (0.60) CYP3A4NPSR1RAB9AKMT2AMEN1
SCHEMBL5923286 0.83 ALDH1A1 (0.47) CYP1A2ALDH1A1NPSR1RAB9AKMT2A
SCHEMBL5923336 0.82 TP53 (0.52) CYP1A2RAB9AKMT2AMEN1NPC1
SCHEMBL5922996 0.79 MAPT (0.57) PHGDHALDH1A1NPSR1RAB9AKMT2A
SCHEMBL5923126 0.77 CHRNB2 (0.50) CYP1A2CYP3A4CHRNB2CHRNB4CHRNA3
SCHEMBL5923192 0.77 TSHR (0.47) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL5923420 0.76 SMN1; SMN2 (0.52) PHGDHALDH1A1NPSR1RAB9AKMT2A
SCHEMBL6518566 0.76 CYP1A2 (0.56) CYP1A2CYP3A4CHRNB2CHRNB4CHRNA3
SCHEMBL5923337 0.75 SCN9A (0.51) RAB9AKMT2AMEN1NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US claimed
WO-2005095345-A2 HETEROARYL GUANIDINES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2005-10-13 — — WO claimed
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication PIGS, GUCY1A1, GUCY1B1 CYP1A2 295/4885CYP3A4 587/4885CHRNB2 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback